Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,701.80 +371.35 (+0.55%) CMC Crypto 200
1,426.23 -2.34 (-0.16%)
CASI Oct 2024 5.000 call
| Previous close | 1.2000 |
| Open | 1.2000 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 5.00 |
| Expiry date | 2024-10-18 |
| Day's range | 1.2000 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
PR NewswireCASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed.
- PR Newswire
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2024.
Simply Wall St.Analysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)
With the business potentially at an important milestone, we thought we'd take a closer look at CASI Pharmaceuticals...
